UNICREDIT BANK/CALL/AMGEN/420/0.1/15.01.25

UNICREDIT BANK/CALL/AMGEN/420/0.1/15.01.25 Stock

DE000HD21R79

Market Closed - Boerse Frankfurt Warrants 01:25:43 2024-06-07 pm EDT
0.32 ^EUR	-8.57%

Current month	-3.03%
3 months	+166.67%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart AMGEN INC.

Chart UNICREDIT BANK/CALL/AMGEN/420/0.1/15.01.25

Latest news about AMGEN INC.

AbbVie's tight grip on Humira market raises concerns about biosimilars	Jun. 07	RE
AMGEN ANNOUNCES POSITIVE RESULTS FOR PHASE 3 REGISTRATIONAL TRIAL EVALUATING UPLIZNA FOR TREATMENT OF IMMUNOGLOBULIN G4-RELATED DISEASE	Jun. 06	AQ
Transcript : Amgen Inc. Presents at Jefferies 2024 Global Healthcare Conference, Jun-06-2024 09:00 AM	Jun. 06
AMGEN TO PRESENT AT GOLDMAN SACHS 45TH ANNUAL GLOBAL HEALTHCARE CONFERENCE	Jun. 05	PR

More news

Quotes 5-day view

Date	Price	Change
24-06-07	0.32	-8.57%
24-06-06	0.35	-5.41%
24-06-05	0.37	+2.78%
24-06-04	0.36	+12.50%
24-06-03	0.32	-3.03%

Real-time Boerse Frankfurt Warrants

Last update June 07, 2024 at 01:25 pm EDT

More quotes

Static data

Product type	Plain-Vanilla-Warrants
Buy / Sell	CALL
Underlying	AMGEN INC.
Issuer	UniCredit
WKN	HD21R7
ISIN	DE000HD21R79
Date issued	2024-01-23
Strike	420 $
Maturity	2025-01-15 (220 Days)
Parity	10 : 1
Emission price	0.59 €
Emission volume	N/A
Settlement	cash
Currency	EUR

Technical Indicators

Highest since issue	0.8 €
Lowest since issue	0.007 €
Spread	0.03 €
Spread %	9.09%

Company Profile

Amgen Inc. is one of the world's leading biotechnology groups. Net sales break down by source of revenue as follows: - drug sales (94.2%): drugs for treating cancer, metabolic disorders, bone diseases, renal failure, hemophilia, etc.; - other (5.8%): primarily royalties. The United States account for 70.3% of net sales.

Sector

More about the company